论文部分内容阅读
通过对１５例慢性肺心病患者服用茶碱控释片（舒弗美）前、后血流动力学、肺功能和血气等进行对照研究发现，舒弗美除能改善症状体征外，还使ＦＶＣ，ＦＶＣ％及ＦＶＣ１％明显增加（Ｐ均＜０．０５），肺血管阻力下降２８％，肺动脉压降低及心排血量有增加趋势。ＳａＯ２，ＰａＯ２和ＳｖＯ２升高（Ｐ均＜０．０５），ＰａＣＯ２略下降。因此舒弗美能明显改善呼吸功能，其肺血管阻力下降除该药有直接扩张肺血管作用外，也可能与呼吸功能改善解除低氧性肺血管收缩有关
By 15 patients with chronic cor pulmonale taking theophylline controlled-release tablets (Shu Weimei) before and after hemodynamics, lung function and blood gas and other control study found that Shu Fumei addition to improving the symptoms and signs, but also make FVC , FVC% and FVC1% increased significantly (all P <0.05), pulmonary vascular resistance decreased 28%, decreased pulmonary arterial pressure and cardiac output increased. SaO2, PaO2 and SvO2 increased (P <0.05), PaCO2 decreased slightly. Therefore, Sfover can significantly improve respiratory function, the decline in pulmonary vascular resistance in addition to the drug has a direct expansion of pulmonary vascular function, may also be related to the improvement of respiratory function to relieve hypoxic pulmonary vasoconstriction